Treatment Patterns and Costs Associated with Chronic Lymphocytic Leukemia Chemotherapy Under the Brazilian Private Health Care Perspective: A Retrospective Analysis of the Orizon Database

Abstract

A407patients received medical services to the value of 927 million Euro or 14.2% of total reimbursed lump-sums (6.53 billion Euros) in Austria. 224 million Euros fall upon medical tumour therapy. With regard to monoclonal antibody therapies, 56 million Euros was refunded. ConClusions: The current development in modern cancer therapies leads to efficient treatment pathways expressed in higher survival rates, reduced hospital days and an improved quality-of-life.